Aflac Inc . reported its fourth-quarter earnings for 2024, revealing that the company's earnings per share (EPS) fell short of expectations despite a strong revenue performance. The EPS came in at $1.

Haemonetics Corporation (market cap: $3.23B) reported its third-quarter earnings for fiscal year 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $1.19, slightly ...